GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000915019 | Prostate | Tumor | purine ribonucleotide metabolic process | 109/3246 | 368/18723 | 3.30e-09 | 1.36e-07 | 109 |
GO:000925918 | Prostate | Tumor | ribonucleotide metabolic process | 110/3246 | 385/18723 | 2.45e-08 | 8.29e-07 | 110 |
GO:000616319 | Prostate | Tumor | purine nucleotide metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:001969318 | Prostate | Tumor | ribose phosphate metabolic process | 111/3246 | 396/18723 | 6.46e-08 | 1.88e-06 | 111 |
GO:007252119 | Prostate | Tumor | purine-containing compound metabolic process | 115/3246 | 416/18723 | 8.47e-08 | 2.31e-06 | 115 |
GO:000915218 | Prostate | Tumor | purine ribonucleotide biosynthetic process | 53/3246 | 169/18723 | 5.62e-06 | 8.63e-05 | 53 |
GO:000926016 | Prostate | Tumor | ribonucleotide biosynthetic process | 54/3246 | 182/18723 | 2.71e-05 | 3.29e-04 | 54 |
GO:000911718 | Prostate | Tumor | nucleotide metabolic process | 120/3246 | 489/18723 | 2.81e-05 | 3.41e-04 | 120 |
GO:000675317 | Prostate | Tumor | nucleoside phosphate metabolic process | 121/3246 | 497/18723 | 3.81e-05 | 4.41e-04 | 121 |
GO:004639016 | Prostate | Tumor | ribose phosphate biosynthetic process | 55/3246 | 190/18723 | 4.89e-05 | 5.42e-04 | 55 |
GO:007252215 | Prostate | Tumor | purine-containing compound biosynthetic process | 55/3246 | 200/18723 | 2.16e-04 | 1.86e-03 | 55 |
GO:000616415 | Prostate | Tumor | purine nucleotide biosynthetic process | 53/3246 | 191/18723 | 2.18e-04 | 1.87e-03 | 53 |
GO:000916514 | Prostate | Tumor | nucleotide biosynthetic process | 61/3246 | 254/18723 | 4.03e-03 | 2.04e-02 | 61 |
GO:190129314 | Prostate | Tumor | nucleoside phosphate biosynthetic process | 61/3246 | 256/18723 | 4.84e-03 | 2.37e-02 | 61 |
GO:000912612 | Prostate | Tumor | purine nucleoside monophosphate metabolic process | 15/3246 | 44/18723 | 5.49e-03 | 2.61e-02 | 15 |
GO:00091676 | Prostate | Tumor | purine ribonucleoside monophosphate metabolic process | 14/3246 | 41/18723 | 7.07e-03 | 3.18e-02 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AMPD1 | SNV | Missense_Mutation | | c.1801C>A | p.Leu601Met | p.L601M | P23109 | protein_coding | tolerated(0.06) | possibly_damaging(0.513) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | | c.1388N>T | p.Gly463Val | p.G463V | P23109 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.1239N>A | p.Asn413Lys | p.N413K | P23109 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | | c.976N>T | p.Asp326Tyr | p.D326Y | P23109 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | rs142123340 | c.1049N>A | p.Arg350His | p.R350H | P23109 | protein_coding | deleterious(0.01) | benign(0.022) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AMPD1 | SNV | Missense_Mutation | rs561023947 | c.524N>A | p.Arg175Gln | p.R175Q | P23109 | protein_coding | tolerated(0.13) | possibly_damaging(0.567) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
AMPD1 | SNV | Missense_Mutation | novel | c.394N>G | p.Ile132Val | p.I132V | P23109 | protein_coding | tolerated(0.69) | benign(0.001) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AMPD1 | SNV | Missense_Mutation | rs149424604 | c.686G>A | p.Arg229Gln | p.R229Q | P23109 | protein_coding | tolerated(0.49) | benign(0.001) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
AMPD1 | SNV | Missense_Mutation | rs192509679 | c.98N>T | p.Thr33Ile | p.T33I | P23109 | protein_coding | deleterious_low_confidence(0) | benign(0.01) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
AMPD1 | SNV | Missense_Mutation | | c.190N>T | p.Asp64Tyr | p.D64Y | P23109 | protein_coding | deleterious(0) | possibly_damaging(0.873) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |